Sclerosis multiplex (SM): vizsgálatok itt: Bulgária
10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Pleven, Plovdiv, Sofiya, Veliko Tirnovo
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Pleven, Plovdiv, Sofiya, Veliko Tirnovo
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - 3. fázisTaking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Blagoevgrad, Pazardzhik, Pleven, Sofiya
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - 3. fázisTaking peopleAn Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
- Where
- Pleven, Sofia, Sofiya
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06675955 · EU 2023-507633-21-01 - 2. fázisTaking peopleMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
- Where
- Blagoevgrad, Burgas, Pleven, Plovdiv, Ruse, Shumen, Sofia, Sofiya, Varna
- Életkor
- 18 év to 64 év
- People
- 230 worldwide
- Run by
- Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00 - 3. fázisTaking peopleA Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
- Where
- Pleven, Sofiya
- Életkor
- 18 év to 64 év
- People
- 125 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Pleven, Sofia
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Blagoevgrad, Pleven, Sofia, Sofiya
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Lovech, Montana, Pleven, Sofia, Sofiya
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00 - 1. fázisNot yet taking people in BulgáriaA Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
- Where
- Pleven, Plovdiv, Sofia, Sofiya
- Életkor
- 18 év to 65 év
- People
- 222 worldwide
- Run by
- Polpharma Biologics International AG
See details and how to joinNCT07606521 · EU 2026-525314-61-00